CN100473662C - 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物 - Google Patents

治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物 Download PDF

Info

Publication number
CN100473662C
CN100473662C CNB038234882A CN03823488A CN100473662C CN 100473662 C CN100473662 C CN 100473662C CN B038234882 A CNB038234882 A CN B038234882A CN 03823488 A CN03823488 A CN 03823488A CN 100473662 C CN100473662 C CN 100473662C
Authority
CN
China
Prior art keywords
seq
coupled receptor
protein coupled
aminoacid sequence
rup41
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038234882A
Other languages
English (en)
Chinese (zh)
Other versions
CN1684975A (zh
Inventor
约翰·W·亚当姆斯
丹尼尔·T·康诺利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN1684975A publication Critical patent/CN1684975A/zh
Application granted granted Critical
Publication of CN100473662C publication Critical patent/CN100473662C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
CNB038234882A 2002-08-01 2003-07-25 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物 Expired - Fee Related CN100473662C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40077402P 2002-08-01 2002-08-01
US60/400,774 2002-08-01

Publications (2)

Publication Number Publication Date
CN1684975A CN1684975A (zh) 2005-10-19
CN100473662C true CN100473662C (zh) 2009-04-01

Family

ID=31495875

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038234882A Expired - Fee Related CN100473662C (zh) 2002-08-01 2003-07-25 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物

Country Status (8)

Country Link
US (2) US7611832B2 (enExample)
EP (1) EP1543025A4 (enExample)
JP (1) JP2005534319A (enExample)
CN (1) CN100473662C (enExample)
AU (1) AU2003259237B2 (enExample)
CA (1) CA2494607A1 (enExample)
TW (3) TW200815603A (enExample)
WO (1) WO2004013285A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2494607A1 (en) 2002-08-01 2004-02-12 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
AU2005301988A1 (en) * 2004-11-08 2006-05-11 University Of Rochester Transgenic non-human animal models of ischemia-reperfusion injury and uses thereof
WO2015131099A1 (en) * 2014-02-28 2015-09-03 The General Hospital Corporation Diagnosis of multiple myeloma and lymphoma
CA2945706C (en) * 2014-04-25 2023-10-24 Libramen Naturals Inc. G-protein coupled receptor 22 transformed cell lines and uses therefor
CN110947003B (zh) * 2017-08-21 2021-04-02 武汉大学 Gpr31抑制剂在制备治疗肾脏缺血再灌注损伤及相关疾病药物中的应用
CN114642668B (zh) * 2020-12-21 2024-04-05 忻佑康医药科技(南京)有限公司 拉坦前列素的药物新用途
CN119351340B (zh) * 2024-10-31 2025-07-08 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) 一种测定rhTSH药物生物学活性的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207126A (zh) * 1995-12-28 1999-02-03 武田药品工业株式会社 G蛋白偶联受体蛋白的配体多肽及其生产方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US5994097A (en) 1997-08-28 1999-11-30 Incyte Pharmaceuticals, Inc. Polynucleotide encoding human G-protein coupled receptor
JP2003531637A (ja) * 2000-05-03 2003-10-28 アストラゼネカ アクチボラグ 方 法
AU2001282894A1 (en) 2000-07-19 2002-01-30 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
WO2002061432A2 (en) 2001-02-01 2002-08-08 Lifespan Biosciences, Inc. Gpr22, a g protein-coupled receptor (gpcr) and compositions and methods related thereto
WO2003065984A2 (en) 2002-02-01 2003-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease
CA2494607A1 (en) 2002-08-01 2004-02-12 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
JP2009511063A (ja) 2005-10-14 2009-03-19 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ２２およびそれに関連する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207126A (zh) * 1995-12-28 1999-02-03 武田药品工业株式会社 G蛋白偶联受体蛋白的配体多肽及其生产方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
the sequence of H. sapiens BAC clone CTB-20D2. Gattung S.NCBI,Vol.AAB63815 . 2000 *

Also Published As

Publication number Publication date
TW200815603A (en) 2008-04-01
TW200800009A (en) 2008-01-01
US20070224127A1 (en) 2007-09-27
JP2005534319A (ja) 2005-11-17
TW200410985A (en) 2004-07-01
TWI291555B (en) 2007-12-21
WO2004013285A3 (en) 2004-06-10
WO2004013285A2 (en) 2004-02-12
US7611832B2 (en) 2009-11-03
EP1543025A2 (en) 2005-06-22
CA2494607A1 (en) 2004-02-12
AU2003259237B2 (en) 2011-01-06
EP1543025A4 (en) 2006-03-15
US20050238579A1 (en) 2005-10-27
AU2003259237A1 (en) 2004-02-23
CN1684975A (zh) 2005-10-19

Similar Documents

Publication Publication Date Title
US20110177612A1 (en) Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders
EA016041B1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
TW200804812A (en) Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
CN100473662C (zh) 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物
US20160077113A1 (en) Methods of Identifying Candidate Compounds of the Human G Protein-Coupled Receptor, GPR50, as Modulators of Body Mass or Adiposity
JP2011162567A (ja) 心血管障害の処置のためのヒトｇタンパク質共役型レセプターおよびそのモジュレーター
US20070232519A1 (en) Human G protein-coupled receptor and modulators thereof for the treatment of cardiovascualr disorders
JP2012167017A (ja) ペプチドおよびその用途
US7700361B2 (en) Secretory or membrane protein expressed in skeletal muscles
US20090313708A1 (en) Gpr22 and methods relating thereto
JP2001309792A (ja) スクリーニング方法
Grämer Development of a GRK2-inhibitory peptide
WO2000029570A1 (fr) Nouvelle proteine et son utilisation
JP2009060787A (ja) Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤
JP2003177127A (ja) Ｇ蛋白質共役型レセプター蛋白質の用途
JP2001149072A (ja) 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
WO2001031004A1 (fr) Nouvelle proteine et son utilisation
JP2002296277A (ja) Ｍｃｈ受容体アンタゴニスト・アゴニストのスクリーニング方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090401

Termination date: 20120725